Kexing Biopharm Co., Ltd.
688136
Rank in Stocks
#12616
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily... Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
Share Price
$2.28
Last synced: 2026-11-13
Market Cap
$452.51M
Change (1 day)
-4.04%
Change (1 year)
-53.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kexing Biopharm Co., Ltd. (688136)
Category
Healthcare
Operating Margin for Kexing Biopharm Co., Ltd. (688136)
Operating Margin as of November 2026 TTM: 7.59%
According to Kexing Biopharm Co., Ltd.'s latest financial reports, its current operating margin (TTM) is 7.59%. At the end of 2025 the company had an operating margin of 11.15%.
Operating Margin history for Kexing Biopharm Co., Ltd. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 7.59% | -31.93% |
| 2025 | 11.15% | 148.33% |
| 2024 | 4.49% | -122.06% |
| 2023 | -20.35% | 93.26% |
| 2022 | -10.53% | -238.01% |
| 2021 | 7.63% | -41.76% |
| 2020 | 13.10% | -17.45% |
| 2019 | 15.87% | 16.52% |
| 2018 | 13.62% | -6.07% |
| 2017 | 14.50% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -125.74% |
US
|
|
| 33.87% | -95.54% |
US
|
|
| -116.04% | -115.29% |
US
|
|
| 25.57% | -96.63% |
AU
|
|
| 31.23% | -95.89% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Kexing Biopharm Co., Ltd.'s operating margin
What is Kexing Biopharm Co., Ltd.'s operating margin?
Kexing Biopharm Co., Ltd.'s operating margin is 7.59%, as of Nov 2026.
What was Kexing Biopharm Co., Ltd.'s operating margin in 2025?
In 2025, Kexing Biopharm Co., Ltd.'s operating margin was 11.15%, compared with 4.49% in 2024.
How has Kexing Biopharm Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Kexing Biopharm Co., Ltd.'s operating margin was highest in 2020 (13.10%) and lowest in 2023 (-20.35%).
How does Kexing Biopharm Co., Ltd.'s operating margin compare with similar companies?
Kexing Biopharm Co., Ltd.'s operating margin (7.59%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.